Arkolith/Insider Trading/RPRX/Form 4

Urist Marshall

EVP, Research & InvestmentsRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Jan 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$816K
Net Open-Market Flow
-$816K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 9, 2026Sell(S)20K$40.78$816K60K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001838139-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML